Voyager Therapeutics (NASDAQ:VYGR) Given Buy Rating at Canaccord Genuity Group

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reissued by investment analysts at Canaccord Genuity Group in a report released on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 112.44% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

VYGR stock traded down $0.10 during trading on Thursday, hitting $6.59. 103,129 shares of the stock traded hands, compared to its average volume of 639,766. The stock has a market cap of $359.37 million, a price-to-earnings ratio of 9.28 and a beta of 0.89. Voyager Therapeutics has a 1 year low of $5.71 and a 1 year high of $11.72. The firm’s 50 day moving average is $6.63 and its two-hundred day moving average is $7.53.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. SummerHaven Investment Management LLC lifted its holdings in shares of Voyager Therapeutics by 2.5% in the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after acquiring an additional 1,921 shares during the last quarter. Hunter Perkins Capital Management LLC grew its position in Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after acquiring an additional 2,025 shares in the last quarter. Finally, Empowered Funds LLC raised its position in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.